Drugs / Zabofloxacin

Trials 4 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02212795 May → Aug 2014 Dong Wha Pharmaceutical Co. Ltd. Completed No outcome recorded
Phase 1 NCT01341249 Apr → May 2011 Seoul National University Hospital Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01081964 Mar 2010 → Apr 2012 IASO Pharma Inc. Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT01658020 Aug 2012 → Jan 2014 chronic obstructive pulmonary disease Dong Wha Pharmaceutical Co. Ltd. Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Zabofloxacin “pharmacokinetics of zabofloxacin, the main component of DW224aa(Test drug) and DW224a(Reference drug).” NCT01341249
3

NCT01081964

NCT01658020

NCT02212795

Known as zabofloxacin aspartate “the zabofloxacin aspartate 488 mg tablet (DW224aa, 366.5 mg as zabofloxacin)” PMID 23865727 Aug 2013
Known as zabofloxacin HCl “The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy, active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl...” NCT01081964
Known as zabofloxacin hydrochloride “the zabofloxacin hydrochloride 400 mg capsule (DW224a, 366.7 mg as zabofloxacin)” PMID 23865727 Aug 2013
Known as Zabofloxacine ChEMBL registry synonym — accepted as the source's own label CHEMBL2107811
Known as Zabofloxacino ChEMBL registry synonym — accepted as the source's own label CHEMBL2107811
Action Inhibit “potent and selective inhibitor of the essential bacterial type II topoisomerases and topoisomerase IV” PMID 23865727 Aug 2013
Modality Small molecule “zabofloxacin (a fluoroquinolone antibiotic)” NCT01081964
Route Oral oral zabofloxacin HCl (400mg)” NCT01081964